ZURICH (Dow Jones) – After the recent weak period, the Swiss stock market recorded small gains on Friday. Since the November peak, the serious mental illness had lost about 300 points, now it has risen slightly. There is still a lack of new stimuli, the old topics of the corona pandemic and vaccine hopes have largely been played out, and the market is hot.
The news that Pfizer will only be able to dispense half as many vaccine doses this year as initially planned is hardly a burden. A slightly friendly accent came from US politics, where the chances of getting a toolkit have risen again as Democrats and Republicans debate again.
The SMI gained 0.2 percent to 10,365 points. In the 20 SMI stocks, there were 10 missing and 10 winners. 41.32 (previously: 52.66) million shares traded.
Pharmaceutical heavyweights Novartis (+0.4 percent) and Roche (+0.9 percent) had a significantly positive overall market share. The main losers from the previous day from the pharmaceutical sector also improved somewhat. Lonza rose 0.8 percent and Alcon rose 1.6 percent.
Amazingly, premium chocolate maker Lindt has proven to be the winner of the corona pandemic. The consumers attached to their homes have probably mixed themselves with sweets. Analysts from Bernstein are forecasting a 14 to 25 percent increase in sales in the U.S. and Europe for the second half of the year. The share price rose 0.8 percent.
The Stifel analysts have taken a closer look at the luxury goods sector and are starting the related stocks with valuations. The two federal titles Richemont and Swatch create only a “hold” recommendation. On Friday, the courses fell 0.5 and 0.4 percent.
Contact the author: [email protected]
DJG / raz / err
(ENDS) Dow Jones Newswires
December 04, 2020 11:42 ET (16:42 GMT)